Veidlapa Nr. M-3 (8)

Study Course Description

Myeloproliferative Oncohematological Diseases

Main Study Course Information

Course Code

RHE_033

Branch of Science

Clinical medicine

ECTS

9.00

Target Audience

Medicine

LQF

Level 8

Study Course Implementer

Course Supervisor

Sandra Lejniece

Residency Speciality

Speciality

Hematologist

Supervisor of Medical Speciality

Sandra Lejniece

Contacts

About Study Course

Objective

Learning Outcomes

Knowledge

1.-

Skills

1.-

Competences

1.-

Assessment

Individual work

Title	% from total grade	Grade
1. Individual work	-	-

Examination

Title	% from total grade	Grade
1. Examination	-	-

Study Course Theme Plan

FULL-TIME

Part 1

Seminar

Modality	Location
-	-

Topics

Seminar

Modality	Location
-	-

Topics

Seminar

Modality	Location
-	-

Topics

Seminar

Modality	Location
-	-

Topics

Seminar

Modality	Location
-	-

Topics

Seminar

Modality	Location
-	-

Topics

Total ECTS (Creditpoints):

9.00

Number of Residency Seminars:

Length (weeks):

Final Examination:

Residency exam (Theory and practice)

Bibliography

Required Reading

Hochhaus, M. Baccarani, R. T. Silver, C. Schiffer, J. F. Apperley, F. Cervantes et al. European LeukemiaNet 2020 recommendations for treatment chronic myeloid leukemia. Leukemia, 2020, 34: 966-984.

Sokal J., Cox E., Baccarani M., et al. Prognostic discrimination in “goodrisk” chronic granulocytic leukemia. Blood 1984; 63:789–799.

Hasford J., Pfirrmann M., Hehlmann R., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90:850–858.

Marin D., Ibrahim A. R., Goldman J. M. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 2011;29:3944–3945.

Geelen I. G. P., Sandin F., Thielen N., Janssen J., Hoogendoorm M., Visser O. et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world”CML patients. Leukemia. 2018; 32:2299-2303.

Hochhaus A., Dreyling M. On behalf of the ESMO Guidelines Working Group. Chronic myelogenous leukemia: ESMO Clinical Recommendations for the diagnosis, treatment and follow-up. Annals of Oncology 19 (Supplement 2): ii63–ii64, 2008 clinical recommendations doi:10.1093/annonc/mdn091

Cross N. C., White H. E., Muller M. C., Saglio G., Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26:2172–2175.

Soverini S., Hochhaus A., et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.Blood, 2011; 118: 1208-1215.

Radich J. P., Deininger M., Abboud C. N., et al. Chronic Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Myeloid Compr Canc Netw. 2018 Sep;16(9):1108-1135.

10.

Passweg J. R., Walker I., Sobocinski K. A., et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125: 613–620.

11.

Gratwohl A., Brand R., Apperley J., Crawley C., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.

12.

Tefferi et al. Polycytthemia vera treatment algorithm. Blood Cancer Journal 2018; 8:3-7.

13.

Benites B. D., Lima C. S., Lorand-Metze I., et al. Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. Clinics (Sao Paulo). 2013; 68(3):339-43. PMID: 23644853

14.

NCCN clinical Practice Guidelins in Oncology. Myeloproliferative Neoplasms. Version 2. 2018.

15.

Passamonti F., Mora B., Barraco D., Maffioli M.. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. Curr Hematol Malig Rep. 2018 Jun;13(3):173-182. doi: 10.1007/s11899-018-0453-y. PMID: 29713873.

Additional Reading

Passamonti F., Giorgino T., Mora B., et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31. PMID: 28561069

Heim D., Ebnöther M., Favre G. Chronische Myeloische Leukämie – Update 2020 [Chronic myeloid leukemia - update 2020]. Ther Umsch. 2019;76(9):503-509. German. doi: 10.1024/0040-5930/a001124. PMID: 32157969.

Zhou T., Medeiros L. J., Hu S. Chronic Myeloid Leukemia: Beyond BCR-ABL1. Curr Hematol Malig Rep. 2018 Dec;13(6):435-445. doi: 10.1007/s11899-018-0474-6. PMID: 30370478.

Zhou H., Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015 Jun;6(6):403-12. doi: 10.1007/s13238-015-0143-7. Epub 2015 Mar 10. PMID: 25749979; PMCID: PMC4444810.

Hijiya N., Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019 May 30;133(22):2374-2384. doi: 10.1182/blood.2018882233. Epub 2019 Mar 27. PMID: 30917954.

Bennour A., Saad A., Sennana H. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays. Crit Rev Oncol Hematol. 2016 Jan;97:263-74. doi: 10.1016/j.critrevonc.2015.08.020. Epub 2015 Aug 29. PMID: 26412717.

Shanmuganathan N., Hiwase D. K., Ross D. M. Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leuk Lymphoma. 2017 Dec;58(12):2799-2810. doi: 10.1080/10428194.2017.1312377. Epub 2017 May 9. PMID: 28482729.

Minami Y. Guest editorial: chronic myeloid leukemia. Int J Hematol. 2018 Oct; 108(4):353-354. doi: 10.1007/s12185-018-2521-4. Epub 2018 Aug 28. PMID: 30155590.

Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. PMID: 33197049.

10.

Yoon S. Y., Won J. H. The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms. Blood Res. 2021 Apr 30;56(S1):S44-S50. doi: 10.5045/br.2021.2020334. PMID: 33935035; PMCID: PMC8093996.

11.

Marcellino B., El Jamal S. M., Mascarenhas J. O. Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clin Adv Hematol Oncol. 2018 Sep;16(9):619-626. PMID: 30256778.

12.

Gilani J. A., Ashfaq M. A., Mansoor A. E., et al. Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics. Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1691-1699. doi: 10.31557/APJCP.2019.20.6.1691. PMID: 31244289; PMCID: PMC7021616.

13.

Parra Salinas I., Recasens Flores V., Montañés M. Á., García-Erce J. A. Therapeutic erythroapheresis: Experience in patients with polycythemia vera and secondary erythrocytosis. Med Clin (Barc). 2020 Jan 10;154(1):16-19. English, Spanish. doi: 10.1016/j.medcli.2018.12.016. Epub 2019 Feb 19. PMID: 30795904.

14.

Faustino F. G., Teixeira R., et al. Acute Myocardial Infarction as First Onset of Polycythemia Vera. Arq Bras Cardiol. 2020 Apr;114(4 Suppl 1):27-30. English, Portuguese. doi: 10.36660/abc.20190104. Epub 2020 May 18. PMID: 32428108.